Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies

Atopic dermatitis experts examine factors that impact coverage decisions for atopic dermatitis (AD) treatments, address challenges providers encounter (such as step-therapy and prior authorization) and offer strategies to streamline the prior authorization process for topical AD therapies.

EP: 1.Tackling Key Concerns in Atopic Dermatitis + Biologic Use

EP: 2.Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape

EP: 3.Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment

EP: 4.Experts Discuss Long-Term Effects and Monitoring in AD Therapy

EP: 5.Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD

EP: 6.The Patient Journey: Effectively Managing AD Itch Early On

Now Viewing

EP: 7.Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies

EP: 8.Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care

1. In addition to cost, what factors influence coverage decisions for AD treatments?
2. How do step-therapy protocols and prior authorization approval process influence the prescribing patterns of topical therapies (and progressing to systemic therapies) for AD among healthcare providers?
3. What strategies can healthcare providers implement to streamline the PA approval process for topical AD therapies and reduce administrative burdens while still ensuring cost-effective care?
   1. Please discuss the burden providers face in terms of workload perspective, staffing constraints, etc, and what this means for patients

Related Videos

Related Content

Advertisement

September 6th 2024

Roflumilast Linked to Higher 5-Year Mortality in Patients With COPD in US, Germany

Brooke McCormick

A small 5-year all-cause mortality risk increase among patients with chronic obstructive pulmonary disease (COPD) using roflumilast was found in Germany and the US.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

September 6th 2024

Research Suggests Psychedelics Are Well Tolerated, but Calls for Improved Monitoring

Giuliana Grossi

While psychedelics like LSD and psilocybin are generally well tolerated in clinical and research settings, study authors suspect inconsistent reporting of adverse events.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

September 6th 2024

ESC Congress 2024 Recap: New Guidelines, Breakthrough Trials, and Personalized Cardiology

Giuliana Grossi

Lead investigators, presenters, and the chair of this year’s European Society of Cardiology Congress, John McMurray, MD, discussed the meeting highlights and recapped important data.

September 6th 2024

ESC 2024: Advancing Care With New Cardiovascular Research

Maggie L. Shaw

At the 2024 European Society of Cardiology Congress (ESC), key research in cardiology care included studies conducted on cardiovascular disease risk among women, cardiac distress and smoking, and lipoprotein(a).

Related Content

Advertisement

September 6th 2024

Roflumilast Linked to Higher 5-Year Mortality in Patients With COPD in US, Germany

Brooke McCormick

A small 5-year all-cause mortality risk increase among patients with chronic obstructive pulmonary disease (COPD) using roflumilast was found in Germany and the US.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

September 6th 2024

Research Suggests Psychedelics Are Well Tolerated, but Calls for Improved Monitoring

Giuliana Grossi

While psychedelics like LSD and psilocybin are generally well tolerated in clinical and research settings, study authors suspect inconsistent reporting of adverse events.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

September 6th 2024

ESC Congress 2024 Recap: New Guidelines, Breakthrough Trials, and Personalized Cardiology

Giuliana Grossi

Lead investigators, presenters, and the chair of this year’s European Society of Cardiology Congress, John McMurray, MD, discussed the meeting highlights and recapped important data.

September 6th 2024

ESC 2024: Advancing Care With New Cardiovascular Research

Maggie L. Shaw

At the 2024 European Society of Cardiology Congress (ESC), key research in cardiology care included studies conducted on cardiovascular disease risk among women, cardiac distress and smoking, and lipoprotein(a).